23:49 , Oct 22, 2018 |  BC Extra  |  Clinical News

Roche reports responses for IL-2 variant at ESMO

A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented Sunday at the European Society for Medical Oncology in Munich from...
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; acute lymphoblastic leukemia (ALL); ovarian cancer; solid tumors Cell culture and mouse studies suggest anti-PD-1 single-chain variable fragment (scFv)-secreting CAR T cells could help treat Burkitt lymphoma, ALL and solid tumors. In co-culture...
17:34 , Aug 3, 2018 |  BC Week In Review  |  Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX). Glycotope will receive an undisclosed upfront payment...
18:16 , Jul 30, 2018 |  BC Extra  |  Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX). Glycotope will receive an undisclosed upfront payment...
18:23 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); ovarian cancer; solid tumors Mouse studies suggest IL-18-secreting CAR T cells could help treat ALL, thymoma and ovarian cancer. In a xenograft mouse model of ALL, CD19-targeting CAR T cells...
23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:04 , Dec 1, 2017 |  BC Week In Review  |  Company News

Daiichi, Glycotope partner for cancer ADC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Glycotope GmbH (Berlin, Germany) partnered to develop an antibody-drug conjugate (ADC) to treat cancer by combining Daiichi's ADC technology with Glycotope's PankoMab-GEX, a humanized IgG1 antibody targeting mucin 1...
17:50 , Nov 2, 2017 |  BC Innovations  |  Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...